Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 344,995
  • Shares Outstanding, K 48,797
  • Annual Sales, $ 45,790 K
  • Annual Income, $ -83,890 K
  • 60-Month Beta 2.80
  • Price/Sales 6.91
  • Price/Cash Flow N/A
  • Price/Book 0.87
Trade CCCC with:

Options Overview Details

View History
  • Implied Volatility 84.92% ( -4.30%)
  • Historical Volatility 95.10%
  • IV Percentile 48%
  • IV Rank 13.99%
  • IV High 237.18% on 06/06/22
  • IV Low 60.15% on 06/13/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 4
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 4,058
  • Open Int (30-Day) 4,279

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.68
  • Number of Estimates 6
  • High Estimate -0.65
  • Low Estimate -0.73
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.84 +46.07%
on 06/16/22
7.82 -9.59%
on 06/08/22
+0.65 (+10.12%)
since 05/24/22
3-Month
4.84 +46.07%
on 06/16/22
26.80 -73.62%
on 04/05/22
-18.08 (-71.89%)
since 03/24/22
52-Week
4.84 +46.07%
on 06/16/22
51.21 -86.19%
on 09/23/21
-30.21 (-81.04%)
since 06/24/21

Most Recent Stories

More News
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -6.56% and 0.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CCCC : 7.07 (+9.10%)
CSTL : 23.83 (+7.78%)
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in...

CCCC : 7.07 (+9.10%)
C4 Therapeutics is Now Oversold (CCCC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

CCCC : 7.07 (+9.10%)
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

– Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected...

CCCC : 7.07 (+9.10%)
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors

– Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee...

CCCC : 7.07 (+9.10%)
Promising Developments in Treating Multiple Myeloma Coming at This Year’s AACR Meeting

VANCOUVER – USA News Group –According to a report from ResearchAndMarkets.com, total cases of the uncommon but deadly blood cancer, multiple myeloma, will continue to rise by 2030. Treatment for the...

ONCY : 1.0100 (-1.23%)
ONC.TO : 1.30 (-2.26%)
CGEN : 2.09 (-0.48%)
CCCC : 7.07 (+9.10%)
AMGN : 245.37 (+0.94%)
JNJ : 182.29 (+1.46%)
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

- Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation – -...

CCCC : 7.07 (+9.10%)
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer...

CCCC : 7.07 (+9.10%)
3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch

Is it time to buy a basket of biotech stocks?

KYMR : 20.13 (+2.70%)
ARVN : 45.80 (+7.97%)
PFE : 51.59 (+2.99%)
SNY : 53.42 (+5.95%)
VRTX : 292.55 (+3.19%)
CCCC : 7.07 (+9.10%)
RHHBY : 41.6400 (+4.07%)
BIIB : 211.93 (+0.26%)
GOOG : 2,370.76 (+5.19%)
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio

– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022– – IND Clearance Achieved for CFT8634, a Degrader Targeting BRD9; On...

CCCC : 7.07 (+9.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics...

See More

Key Turning Points

3rd Resistance Point 8.17
2nd Resistance Point 7.65
1st Resistance Point 7.36
Last Price 7.07
1st Support Level 6.55
2nd Support Level 6.03
3rd Support Level 5.74

See More

52-Week High 51.21
Fibonacci 61.8% 33.50
Fibonacci 50% 28.02
Fibonacci 38.2% 22.55
Last Price 7.07
52-Week Low 4.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar